Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Testis Cancer. National Cancer Institute. Available at http://seer.cancer.gov/statfacts/html/testis.html. Accessed: jUNE 24, 2023.
Stephenson AJ, Gilligan TD. Neoplasms of the Testis. Wein AJ, Kavoussi LR, Partin AW, Peters CA, eds. Campbell-Walsh Urology. 11th ed. Philadelphia, PA: Elsevier; 2016. 784-811.
Hanna NH, Einhorn LH. Testicular cancer--discoveries and updates. N Engl J Med. 2014 Nov 20. 371 (21):2005-16. [QxMD MEDLINE Link]. [Full Text].
Pettersson A, Richiardi L, Nordenskjold A, et al. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. 2007 May 3. 356(18):1835-41. [QxMD MEDLINE Link].
McKiernan JM, Goluboff ET, Liberson GL, et al. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol. 1999 Aug. 162(2):361-3. [QxMD MEDLINE Link].
Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol. 2014 Jun. 65(6):1095-106. [QxMD MEDLINE Link]. [Full Text].
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997 Feb. 15 (2):594-603. [QxMD MEDLINE Link].
Mykletun A, Dahl AA, Haaland CF, et al. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol. 2005 May 1. 23(13):3061-8. [QxMD MEDLINE Link].
Beck SD, Foster RS, Bihrle R, Donohue JP. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors. Urology. 2007 Mar. 69(3):557-9. [QxMD MEDLINE Link].
Tsili AC, Tsampoulas C, Giannakopoulos X, et al. MRI in the histologic characterization of testicular neoplasms. AJR Am J Roentgenol. 2007 Dec. 189(6):W331-7. [QxMD MEDLINE Link].
Sanchez D, Zudaire JJ, Fernandez JM, et al. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int. 2002 Jun. 89(9):912-6. [QxMD MEDLINE Link].
Testis. Amin MB, Edge SB, Compton CC, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 735-746.
Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol. 2007 Apr 10. 25(11):1310-5. [QxMD MEDLINE Link].
Sohaib SA, Koh DM, Barbachano Y, Parikh J, Husband JE, Dearnaley DP, et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol. 2009 Apr. 64(4):362-7. [QxMD MEDLINE Link].
Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005 Apr 20. 23(12):2781-8. [QxMD MEDLINE Link].
Horwich A, Norman A, Fisher C, et al. Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. J Urol. 1994 Jan. 151(1):72-7; discussion 77-8. [QxMD MEDLINE Link].
[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: Testicular Cancer Version 1.2023. NCCN. Available at https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf. January 26, 2023; Accessed: June 24, 2023.
Dieckmann KP, et al. Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. Ther Adv Med Oncol. 2022. 14:17588359221086813. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Laguna MP, Albers P, Albrecht F, et al. Guidelines on Testicular Cancer. European Association of Urology. Available at https://uroweb.org/guideline/testicular-cancer/. 2023; Accessed: June 24, 2023.
Pagliaro LC. Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors. J Clin Oncol. 2017 Apr 1. 35 (10):1036-1040. [QxMD MEDLINE Link].
Masterson TA, Shayegan B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ, et al. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology. 2012 Jan. 79(1):156-9. [QxMD MEDLINE Link].
O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003 Jan. 14(1):91-6. [QxMD MEDLINE Link].
van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007 Oct 1. 25 (28):4370-8. [QxMD MEDLINE Link].
Miki T, Mizutani Y, Nakamura T, Kawauchi A, Nagahara A, Nonomura N, et al. Post-chemotherapy nerve-sparing retroperitoneal lymph node dissection for advanced germ cell tumor. International Journal of Urology. April 2009. 16:379-382. [QxMD MEDLINE Link].
Janetschek G, Hobisch A, Peschel R, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol. 2000 Jun. 163(6):1793-6. [QxMD MEDLINE Link].
Neyer M, Peschel R, Akkad T, et al. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer. J Endourol. 2007 Feb. 21(2):180-3. [QxMD MEDLINE Link].
Shayegan B, Carver BS, Stasi J, et al. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. BJU Int. 2007 May. 99(5):993-7. [QxMD MEDLINE Link].
Schirren J, Trainer S, Eberlein M, Lorch A, Beyer J, Bölükbas S. The Role of Residual Tumor Resection in the Management of Nonseminomatous Germ Cell Cancer of Testicular Origin. Thorac Cardiovasc Surg. 2012 Mar 1. [QxMD MEDLINE Link].
Permpongkosol S, Lima GC, Warlick CA, et al. Postchemotherapy laparoscopic retroperitoneal lymph node dissection: evaluation of complications. Urology. 2007 Feb. 69(2):361-5. [QxMD MEDLINE Link].
Djaladat H, Burner E, Parikh PM, Beroukhim Kay D, Hays K. The Association Between Testis Cancer and Semen Abnormalities Before Orchiectomy: A Systematic Review. J Adolesc Young Adult Oncol. 2014 Dec 1. 3 (4):153-159. [QxMD MEDLINE Link].
Phillips N, Jequier AM. Early testicular cancer: a problem in an infertility clinic. Reprod Biomed Online. 2007 Nov. 15(5):520-5. [QxMD MEDLINE Link].
Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urol. 2005 Nov. 174(5):1819-22; discussion 1822. [QxMD MEDLINE Link].
Spermon JR, Kiemeney LA, Meuleman EJ, et al. Fertility in men with testicular germ cell tumors. Fertil Steril. 2003 Jun. 79 Suppl 3:1543-9. [QxMD MEDLINE Link].
Gandini L, Sgro P, Lombardo F, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod. 2006 Nov. 21(11):2882-9. [QxMD MEDLINE Link].
Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer. 2004 Feb 15. 100(4):732-7. [QxMD MEDLINE Link].
Sakamoto H, Oohta M, Inoue K, et al. Testicular sperm extraction in patients with persistent azoospermia after chemotherapy for testicular germ cell tumor. Int J Urol. 2007 Feb. 14(2):167-70. [QxMD MEDLINE Link].
Schmidt KL, Carlsen E, Andersen AN. Fertility treatment in male cancer survivors. Int J Androl. 2007 Aug. 30(4):413-8; discussion 418-9. [QxMD MEDLINE Link].
Ehrlich Y, Rosenbaum E, Baniel J. Late relapse of testis cancer. Curr Urol Rep. 2013 Oct. 14 (5):518-24. [QxMD MEDLINE Link].